de en
  • Paion GmbH
  • Company

    About PAION

    1. History
    2. Management
    3. Supervisory Board

    Contact

    1. Germany
    2. UK

    Career

    1. What does PAIONeering mean to us?
    2. What PAIONeers can expect
    3. Job offers

    Information

    1. Events
    2. Information Request
  • Remimazolam

    Sedation & anesthesia market

    1. Overview
    2. Procedural Sedation (U.S.)
    3. General Anesthesia (Europe)
    4. ICU sedation

    Product Information

    1. About Remimazolam
    2. Clinical trials

    Medical Information

  • Pipeline

    Portfolio

    1. Overview
    2. Remimazolam

    Glossary

    1. A_Z
  • Partnering

    Strategy

    1. Partnering strategy
    2. Remimazolam strategy

    Licensing projects

    1. Remimazolam
  • Media and Investors

    At a glance

    1. General Information
    2. Contact

    Newsroom

    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company

    Information on shares

    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition

    Investorcenter

    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request

    Corporate Governance

    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct

    Annual general meeting

    2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

<span lang="EN-GB"></span>

<font face="Times New Roman" size="3"> </font>
<span lang="EN-GB"></span>

 

 

<span lang="EN-GB"></span>

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

prev next
  • Media and Investors  » 
  • Newsroom  » 
  • Ad-hoc Releases  » 
  • 2016
  • 02/09/2016 15:11

    PAION discontinues European Remimazolam Phase III Trial in cardiac surgery patients due to insufficient recruitment

    • PDF

  • 02/18/2016 15:11

    PAION reports about positive pre-NDA meeting with Japanese authority PMDA

    • PDF

  • 04/11/2016 15:11

    PAION successfully completes patient recruitment in Phase III study with Remimazolam for procedural sedation during colonoscopy

    • PDF

  • 06/19/2016 15:11

    PAION reports positive remimazolam headline data in pivotal U.S. Phase III study in procedural sedation for colonoscopy

    • PDF

  • 06/24/2016 18:20

    PAION grants Cosmo Pharmaceuticals Remimazolam license in the U.S. and Cosmo becomes largest Shareholder of PAION AG

    • PDF

  • 12/19/2016 19:38

    PAION successfully completes patient recruitment in U.S. clinical safety trial of remimazolam in high-risk patients undergoing colonoscopy

    • PDF

  • copyright © PAION AG I all rights reserved
  • Imprint
  • Privacy Statement
  • General Terms and Conditions
Paion

Martinstrasse 10-12 | 52062 Aachen | Deutschland

Tel.: +49 241 4453-0 | Fax.: +49 241 4453-100 | e-mail: info@paion.com

Company
  1. About PAION +
    1. History
    2. Management
    3. Supervisory Board
  2. Contact +
    1. Germany
    2. UK
  3. Career +
    1. What does PAIONeering mean to us?
    2. What PAIONeers can expect
    3. Job offers
  4. Information +
    1. Events
    2. Information Request
Remimazolam
  1. Sedation & anesthesia market +
    1. Overview
    2. Procedural Sedation (U.S.)
    3. General Anesthesia (Europe)
    4. ICU sedation
  2. Product Information +
    1. About Remimazolam
    2. Clinical trials
  3. Medical Information
Pipeline
  1. Portfolio +
    1. Overview
    2. Remimazolam
  2. Glossary +
    1. A_Z
Partnering
  1. Strategy +
    1. Partnering strategy
    2. Remimazolam strategy
  2. Licensing projects +
    1. Remimazolam
Media and Investors
  1. At a glance +
    1. General Information
    2. Contact
  2. Newsroom +
    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company
  3. Information on shares +
    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition
  4. Investorcenter +
    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request
  5. Corporate Governance +
    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
  6. Annual general meeting +
    1. 2019
    2. 2018
    3. 2017
    4. 2016
    5. 2015
    6. 2014
    7. 2013
    8. 2012
    9. 2011
    10. 2010
    11. 2009
    12. 2008